Early outpatient treatment of COVID-19 – IppocrateOrg
… The pandemic … was declared in march 2020
… pathophysiology soon provided a strong rationale for the early use of anti-inflammatory, antiplatelet and anticoagulant drugs
… the evidence was only slowly and partially incorporated into institutional guidelines
… a sample of COVID-19 patients taken care of in Italy by physicians volunteering within the IppocrateOrg Association, one of the main international assistance networks
… between 1st november 2020 and 31st march 2021
… in COVID-19 stage 0 (15,6%), 1 (50,0%), 2a (28,8%), 2b (5,6%)
… overweight (26%) or obese (11,5%)
… chronic comorbidities (34,9%), mainly cardiovascular (23%) and metabolic (13,3%)
… Hospitalization occurred in 5,8% of total cases, mainly in patients taken care of when in stage 2b
… 390 patients (99,6%) recovered, one patient (0,2%) was lost at follow up, and one patient (0,2%) died after hospitalization
… COVID-19 lethality in our cohort was 0,2%, while the overall COVID-19 lethality in Italy in the same period was between 3% and 3,8%
